AJP - Endo Ad Instruments
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am J Physiol Endocrinol Metab 297: E1147-E1153, 2009. First published August 25, 2009; doi:10.1152/ajpendo.00327.2009
0193-1849/09 $8.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
297/5/E1147    most recent
00327.2009v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Shamhart, P. E.
Right arrow Articles by Meszaros, J. G.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shamhart, P. E.
Right arrow Articles by Meszaros, J. G.

Impact of type 1 diabetes on cardiac fibroblast activation: enhanced cell cycle progression and reduced myofibroblast content in diabetic myocardium

Patricia E. Shamhart,1,2 Daniel J. Luther,1,2 Ben R. Hodson,1 John C. Koshy,1 Vahagn Ohanyan,1 and J. Gary Meszaros1,2

1Department of Integrative Medical Sciences, Northeastern Ohio Universities College of Medicine, Rootstown; and 2Graduate Program, School of Biomedical Sciences, Kent State University, Kent, Ohio

Submitted 19 May 2009 ; accepted in final form 18 August 2009

Diabetic patients are prone to developing myocardial fibrosis and suffer from decreased wound healing capabilities. The purpose of this study was to determine whether diabetes alters cardiac fibroblast activity in the myocardium in a 6-wk streptozotocin-induced type 1 diabetic model. In vivo echocardiography indicated significant dilation of the left ventricle (LV) in the diabetic animals, while cardiac function was comparable to that in the normal group. We isolated cardiac fibroblasts from diabetic and control hearts and observed increased proliferation of the diabetic fibroblasts. Microarray analysis using mRNA collected from whole LVs revealed downregulation of known inhibitors of proliferation, p53 and p21, in the diabetic group, consistent with our proliferation data. Western blot analysis confirmed a reduction in p53 protein expression in the diabetic hearts compared with control. We explored the potential signaling underlying the downregulation of these cell cycle mediators and determined that activated Akt, a signal that inhibits p53, was elevated in the diabetic group. Surprisingly, the hearts from the diabetic group contained lower levels of the myofibroblast marker {alpha}-smooth muscle actin ({alpha}-SMA) and higher levels of desmin and platelet endothelial cell adhesion molecule (PECAM). The isolated fibroblasts from the diabetic group also contained significantly less {alpha}-SMA. These data suggest that early-stage diabetic hearts contain highly proliferative fibroblasts, which predisposes the diabetic myocardium to fibrosis, but have fewer myofibroblasts, which may compromise wound healing.

cardiac remodeling; fibrosis; cell growth; hyperglycemia; p53; Akt


Address for reprint requests and other correspondence: J. G. Meszaros, Northeastern Ohio Universities College of Medicine, Dept. of Integrative Biomedical Sciences, 4209 State Route 44, Rootstown, OH 44272-0095 (e-mail: jgmeszar{at}neoucom.edu).






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2009 by the American Physiological Society.